• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于分量的删失复合终点的统计方法。

Statistical approaches for component-wise censored composite endpoints.

机构信息

Division of Biostatistics, School of Public Health, University of Minnesota, Minneapolis, MN, USA.

出版信息

Clin Trials. 2024 Oct;21(5):595-603. doi: 10.1177/17407745241265628. Epub 2024 Aug 8.

DOI:10.1177/17407745241265628
PMID:39115164
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11533687/
Abstract

Composite endpoints defined as the time to the earliest of two or more events are often used as primary endpoints in clinical trials. Component-wise censoring arises when different components of the composite endpoint are censored differently. We focus on a composite of death and a non-fatal event where death time is right censored and the non-fatal event time is interval censored because the event can only be detected during study visits. Such data are most often analysed using methods for right censored data, treating the time the non-fatal event was first detected as the time it occurred. This can lead to bias, particularly when the time between assessments is long. We describe several approaches for estimating the event-free survival curve and the effect of treatment on event-free survival via the hazard ratio that are specifically designed to handle component-wise censoring. We apply the methods to a randomized study of breastfeeding versus formula feeding for infants of mothers infected with human immunodeficiency virus.

摘要

复合终点定义为最早发生的两个或多个事件的时间,通常被用作临床试验的主要终点。当复合终点的不同组成部分以不同的方式进行删失时,就会出现按组成部分删失。我们关注的是死亡和非致死事件的复合终点,其中死亡时间是右删失的,非致死事件时间是区间删失的,因为只有在研究访视期间才能检测到该事件。此类数据通常使用右删失数据的方法进行分析,将首次检测到非致死事件的时间视为事件发生的时间。这可能会导致偏差,尤其是当评估之间的时间间隔较长时。我们描述了几种通过危险比估计无事件生存曲线和治疗对无事件生存影响的方法,这些方法专门用于处理按组成部分删失。我们将这些方法应用于一项针对母亲感染人类免疫缺陷病毒的婴儿进行母乳喂养与配方奶喂养的随机研究。

相似文献

1
Statistical approaches for component-wise censored composite endpoints.基于分量的删失复合终点的统计方法。
Clin Trials. 2024 Oct;21(5):595-603. doi: 10.1177/17407745241265628. Epub 2024 Aug 8.
2
Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules.存在不同访视计划时,带有分量级删失的复合终点分析。
Stat Med. 2022 Apr 30;41(9):1599-1612. doi: 10.1002/sim.9312. Epub 2022 Jan 18.
3
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.在随机试验中具有分量式删失的复合时事件终点的 Cox 回归模型的性能。
Clin Trials. 2023 Oct;20(5):507-516. doi: 10.1177/17407745231177046. Epub 2023 May 26.
4
A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.以无进展生存期作为区间删失的事件发生时间终点的统计问题综述。
J Biopharm Stat. 2013;23(5):986-1003. doi: 10.1080/10543406.2013.813524.
5
Nonparametric estimation in an illness-death model with component-wise censoring.带有分量删失的患病-死亡模型中的非参数估计。
Biometrics. 2022 Sep;78(3):1168-1180. doi: 10.1111/biom.13482. Epub 2021 May 18.
6
Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.通过评估信息性删失对 PRECISION 中主要估计量的影响来增强临床试验结果的可解释性。
Clin Trials. 2020 Oct;17(5):535-544. doi: 10.1177/1740774520934747. Epub 2020 Jul 9.
7
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
8
Composite event-free-survival as an endpoint in oncology drug evaluation: Review and guidance perspectives from the Haute Autorité de Santé (HAS).肿瘤药物评估中复合无事件生存作为终点:来自法国国家药品与健康产品安全署( HAS )的综述和指导观点。
Eur J Cancer. 2024 Jun;204:114047. doi: 10.1016/j.ejca.2024.114047. Epub 2024 Apr 12.
9
Impact of weighted composite compared to traditional composite endpoints for the design of randomized controlled trials.与传统复合终点相比,加权复合终点对随机对照试验设计的影响。
Stat Methods Med Res. 2015 Dec;24(6):980-8. doi: 10.1177/0962280211436004. Epub 2012 Jan 24.
10
Misspecification of Cox regression models with composite endpoints.复合终点的 Cox 回归模型的误指定。
Stat Med. 2012 Dec 10;31(28):3545-62. doi: 10.1002/sim.5436. Epub 2012 Jun 27.

本文引用的文献

1
Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.在随机试验中具有分量式删失的复合时事件终点的 Cox 回归模型的性能。
Clin Trials. 2023 Oct;20(5):507-516. doi: 10.1177/17407745231177046. Epub 2023 May 26.
2
Analysis of composite endpoints with component-wise censoring in the presence of differential visit schedules.存在不同访视计划时,带有分量级删失的复合终点分析。
Stat Med. 2022 Apr 30;41(9):1599-1612. doi: 10.1002/sim.9312. Epub 2022 Jan 18.
3
Nonparametric estimation in an illness-death model with component-wise censoring.带有分量删失的患病-死亡模型中的非参数估计。
Biometrics. 2022 Sep;78(3):1168-1180. doi: 10.1111/biom.13482. Epub 2021 May 18.
4
Event-Free Survival, a Prostate-Specific Antigen-Based Composite End Point, Is Not a Surrogate for Overall Survival in Men With Localized Prostate Cancer Treated With Radiation.无事件生存,一种基于前列腺特异性抗原的复合终点,不能替代局部前列腺癌男性接受放疗后的总生存。
J Clin Oncol. 2020 Sep 10;38(26):3032-3041. doi: 10.1200/JCO.19.03114. Epub 2020 Jun 18.
5
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.评估新型降糖疗法治疗 2 型糖尿病心血管风险的监管指导意见的影响:经验教训与未来方向。
Circulation. 2020 Mar 10;141(10):843-862. doi: 10.1161/CIRCULATIONAHA.119.041022. Epub 2020 Jan 29.
6
Design of cancer trials based on progression-free survival with intermittent assessment.基于无进展生存期和间歇性评估的癌症试验设计。
Stat Med. 2018 May 30;37(12):1947-1959. doi: 10.1002/sim.7641. Epub 2018 Mar 26.
7
Cost-effectiveness Analysis in R Using a Multi-state Modeling Survival Analysis Framework: A Tutorial.使用多状态建模生存分析框架在R中进行成本效益分析:教程
Med Decis Making. 2017 May;37(4):340-352. doi: 10.1177/0272989X16651869. Epub 2016 Jun 8.
8
Sieve estimation in a Markov illness-death process under dual censoring.双重删失下马尔可夫疾病-死亡过程中的筛法估计
Biostatistics. 2016 Apr;17(2):350-63. doi: 10.1093/biostatistics/kxv042. Epub 2015 Nov 22.
9
Bias in progression-free survival analysis due to intermittent assessment of progression.由于对疾病进展的间歇性评估导致无进展生存期分析中的偏倚。
Stat Med. 2015 Oct 30;34(24):3181-93. doi: 10.1002/sim.6529. Epub 2015 May 24.
10
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials.癌症临床试验实例中的替代终点统计评估。
Biom J. 2016 Jan;58(1):104-32. doi: 10.1002/bimj.201400049. Epub 2015 Feb 12.